Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sepetaprost - Santen Pharmaceutical

Drug Profile

Sepetaprost - Santen Pharmaceutical

Alternative Names: DE 126; ONO 9054

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Ono Pharmaceutical; Santen Pharmaceutical
  • Class Eye disorder therapies; Oxepins; Prostaglandins
  • Mechanism of Action Prostaglandin E EP3 receptor agonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 08 Aug 2017 Chemical structure information added
  • 25 Jul 2017 Santen initiates the phase IIb Angel trial for Open angle glaucoma and Ocular hypertension in USA (NCT03216902)
  • 11 Jul 2017 Santen plans a phase IIb trial (Angel study) for Open angle glaucoma and Ocular hypertension in USA in July 2017 (NCT03216902)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top